46

DAFTAR PUSTAKA

Abdelrazik, N., Fouda, M., 2007. Once weekly recombinant human erythropoietin
treatment for cancer-induced anemia in children with acute lymphoblastic
leukemia receiving maintenance chemotherapy: a randomized case-
controlled study: Hematology. (12):533-41.

Acha-Orbea Het al. 2008, Basic concepts in immunology, dalam Murphy K,

Travers P, dan Walport M (Editor), Janeway's immunobiology: New York,
Garland Science, hal. 1-27.

Agyeman, P., Aebi, C., Hirt, A., Niggli, F.K., Nadal, D., Simon, A.et al. 2011.
Predicting bacteremia in children with cancer and fever in chemotherapy-
induced neutropenia: results of the prospective multicenter SPOG 2003 FN
study: Pediatr.Infect.Dis.J (30):e114-e119.

Ali, K., Sutaryo, S., Purwanto, I., Mulatsih, S., Supriyadi, E., Widjajanto, P.H.et
al. 2010. Yogyakarta Pediatric Cancer Registry: an international
collaborative project of University Gadjah Mada, University of
Saskatchewan, and the Saskatchewan Cancer Agency: Asian Pac.J Cancer
Prev (11):131-6.

Asim, M., Zaidi, A., Ghafoor, T., Qureshi, Y., 2011. Death analysis of childhood
acute lymphoblastic leukaemia; experience at Shaukat Khanum Memorial
Cancer Hospital and Research Centre, Pakistan: J Pak.Med.Assoc. (61):666-
70.

Bakhshi, S., Padmanjali, K.S., Arya, L.S., 2008. Infections in childhood acute
lymphoblastic leukemia: an analysis of 222 febrile neutropenic episodes:
Pediatr.Hematol.Oncol. (25):385-92.

Basu, S.K., Fernandez, I.D., Fisher, S.G., Asselin, B.L., Lyman, G.H., 2005.
Length of stay and mortality associated with febrile neutropenia among
children with cancer: J.Clin.Oncol. (23):7958-66.

Blay, J.Y., Chauvin, F., Le, C.A., Anglaret, B., Bouhour, D., Lasset, C.et al.
1996. Early lymphopenia after cytotoxic chemotherapy as a risk factor for
febrile neutropenia: J Clin.Oncol. (14):636-43.
 47

Choi, C.W., Sung, H.J., Park, K.H., Yoon, S.Y., Kim, S.J., Oh, S.C.et al. 2003.
Early lymphopenia as a risk factor for chemotherapy-induced febrile
neutropenia: Am.J Hematol. (73):263-6.

Crawford, J., Dale, D.C., Kuderer, N.M., Culakova, E., Poniewierski, M.S.,
Wolff, D.et al. 2008. Risk and timing of neutropenic events in adult cancer
patients receiving chemotherapy: the results of a prospective nationwide
study of oncology practice: J Natl.Compr.Canc.Netw. (6):109-18.

Dahlan S, 2008, Analisis regresi logistik, Statistik untuk Kedokteran dan

Kesehatan: Jakarta, Salemba Medika, hal. 183-93.

Donadieu, J., Auclerc, M.F., Baruchel, A., Perel, Y., Bordigoni, P., Landman-
Parker, J.et al. 2000. Prognostic study of continuous variables (white blood
cell count, peripheral blast cell count, haemoglobin level, platelet count and
age) in childhood acute lymphoblastic leukaemia. Analysis Of a population
of 1545 children treated by the French Acute Lymphoblastic Leukaemia
Group (FRALLE): Br.J Cancer (83):1617-22.

Ervina, Purnamasari , Puspitasari, 2012. Association between hematologic

parameter of the admission with febrile neutropenia in children with
malignancy: Pediatrica Indonesiana (52):107.

Eyrich, M., Wiegering, V., Lim, A., Schrauder, A., Winkler, B., Schlegel, P.G.,
2009. Immune function in children under chemotherapy for standard risk
acute lymphoblastic leukaemia - a prospective study of 20 paediatric
patients: Br.J Haematol. (147):360-70.

Giovannetti, E., Ugrasena, D.G., Supriyadi, E., Vroling, L., Azzarello, A., de,
L.D.et al. 2008. Methylenetetrahydrofolate reductase (MTHFR) C677T and
thymidylate synthase promoter (TSER) polymorphisms in Indonesian
children with and without leukemia: Leuk.Res. (32):19-24.

Gupta, S., Bonilla, M., Fuentes, S.L., Caniza, M., Howard, S.C., Barr, R.et al.
2009. Incidence and predictors of treatment-related mortality in paediatric
acute leukaemia in El Salvador: Br.J Cancer (100):1026-31.

Gupta, S., Bonilla, M., Valverde, P., Fu, L., Howard, S.C., Ribeiro, R.C.et al.
2012. Treatment-related mortality in children with acute myeloid leukaemia
in Central America: incidence, timing and predictors: Eur.J.Cancer
(48):1363-9.
 48

Hassan, Yusoff Z., Othman s. Fever/Clinical Signs and Association with

Neutropenia in Solid
Cancer Patients - Bacterial Infection as the Main Cause. Asian Pac.J.Cancer Prev.
11, 1273-7. 2010.

Irken, G., Oren, H., Gulen, H., Duman, M., Ucar, C., Atabay, B.et al. 2002.
Treatment outcome of adolescents with acute lymphoblastic leukemia:
Ann.Hematol. (81):641-5.

Jain, V., Dubey, A.P., Gupta, S.K., 2003. Nutritional parameters in children with
malignancy: Indian Pediatr. (40):976-84.

Klaassen, R.J., Goodman, T.R., Pham, B., Doyle, J.J., 2000. "Low-risk"
prediction rule for pediatric oncology patients presenting with fever and
neutropenia: J Clin.Oncol. (18):1012-9.

Klastersky, J., 2004. Management of fever in neutropenic patients with different

risks of complications: Clin.Infect.Dis. (39 Suppl 1):S32-S37.

Kondo, M., Oshita, F., Kato, Y., Yamada, K., Nomura, I., Noda, K., 1999. Early
monocytopenia after chemotherapy as a risk factor for neutropenia: Am.J
Clin.Oncol. (22):103-5.

Lanzkowsky, 2005, Leukemias, Manual of Pediatric Hematology and Oncology:

California, Elsevier Academic Press, hal. 415-52.

Lausen, B., Schmiegelow, K., Andreassen, B., Madsen, H.O., Garred, P., 2006.
Infections during induction therapy of childhood acute lymphoblastic
leukemia--no association to mannose-binding lectin deficiency: Eur.J
Haematol. (76):481-7.

Lyman, G.H., Lyman, C.H., Agboola, O., 2005. Risk models for predicting
chemotherapy-induced neutropenia: Oncologist. (10):427-37.

Lyman, G.H., Rolston, K.V., 2010. How we treat febrile neutropenia in patients
receiving cancer chemotherapy: J.Oncol.Pract. (6):149-52.

Mazur, B., Olejnik, I., Wylezol, I., Sonta-Jakimczyk, D., Szczepanski, T., Karpe,
J., 2003. Assessment of chosen parameters of the immune system in
children with acute lymphoblastic leukemia: Pediatr.Hematol.Oncol.
(20):303-8.
 49

Meckler, G., Lindemulder, S., 2009. Fever and neutropenia in pediatric patients
with cancer: Emerg.Med.Clin.North Am. (27):525-44.

Mendes, Sapolnik. New guidelines for the clinical management of febrile

neutropenia and sepsis in pediatric oncology patients. 83, S54-S63. 2007.

Molgaard-Hansen, L., Mottonen, M., Glosli, H., Jonmundsson, G.K.,

Abrahamsson, J., Hasle, H., 2010. Early and treatment-related deaths in
childhood acute myeloid leukaemia in the Nordic countries: 1984-2003:
Br.J Haematol. (151):447-59.

Moreau, M., Klastersky, J., Schwarzbold, A., Muanza, F., Georgala, A., Aoun,
M.et al. 2009. A general chemotherapy myelotoxicity score to predict
febrile neutropenia in hematological malignancies: Ann.Oncol. (20):513-9.

Oguz, A., Karadeniz, C., Ckitak, E.C., Cil, V., 2006. Which one is a risk factor for
chemotherapy-induced febrile neutropenia in childhood solid tumors: early
lymphopenia or monocytopenia?: Pediatr.Hematol.Oncol. (23):143-51.

Osmani, A.H., Ansari, T.Z., Masood, N., Ahmed, B., 2012. Outcome of febrile
neutropenic patients on granulocyte colony stimulating factor in a tertiary
care hospital: Asian Pac.J Cancer Prev (13):2523-6.

Paganini, H.R., Aguirre, C., Puppa, G., Garbini, C., Javier, R.G., Ensinck, G.et al.
2007. A prospective, multicentric scoring system to predict mortality in
febrile neutropenic children with cancer: Cancer (109):2572-9.

Permono, Ugrasena, 2006, Leukemia akut, dalam Permono B, Sutaryo, Ugrasena

IDG, Windiastuti E, dan Abdulsalam M (Editor), Buku Ajar Hematologi-
Onkologi Anak: Jakarta, Ikatan Dokter Anak Indonesia, hal. 236-47.

Prucker, C., Attarbaschi, A., Peters, C., Dworzak, M.N., Potschger, U., Urban,
C.et al. 2009. Induction death and treatment-related mortality in first
remission of children with acute lymphoblastic leukemia: a population-
based analysis of the Austrian Berlin-Frankfurt-Munster study group:
Leukemia (23):1264-9.

Pui, C.H., Relling, M.V., Downing, J.R., 2004. Acute lymphoblastic leukemia:
N.Engl.J Med. (350):1535-48.

Rackoff, W.R., Gonin, R., Robinson, C., Kreissman, S.G., Breitfeld, P.B., 1996.
Predicting the risk of bacteremia in childen with fever and neutropenia: J
Clin.Oncol. (14):919-24.
 50

Ray-Coquard, I., Borg, C., Bachelot, T., Sebban, C., Philip, I., Clapisson, G.et al.
2003. Baseline and early lymphopenia predict for the risk of febrile
neutropenia after chemotherapy: Br.J Cancer (88):181-6.

Rivera-Luna, R., Olaya-Vargas, A., Velasquez-Avina, M., Frenk, S., Cardenas-

Cardos, R., Leal-Leal, C.et al. 2008. Early death in children with acute
lymphoblastic leukemia: does malnutrition play a role?:
Pediatr.Hematol.Oncol. (25):17-26.

Rondinelli, P.I., Ribeiro, K.C., de, C.B., 2006. A proposed score for predicting
severe infection complications in children with chemotherapy-induced
febrile neutropenia: J Pediatr.Hematol.Oncol. (28):665-70.

Rubnitz, J.E., Lensing, S., Zhou, Y., Sandlund, J.T., Razzouk, B.I., Ribeiro,
R.C.et al. 2004. Death during induction therapy and first remission of acute
leukemia in childhood: the St. Jude experience: Cancer (101):1677-84.

Rumiris, Dewi, larasati, Andarsini, Ugrasena, Permono, 2012. Bacterial infection

and mortality in acute lymphoblastic leukemia with febrile neutropenia:
Pediatrica Indonesiana (52):132.

Safdar, A., Rodriguez, G.H., Lichtiger, B., Dickey, B.F., Kontoyiannis, D.P.,
Freireich, E.J.et al. 2006. Recombinant interferon gamma1b immune
enhancement in 20 patients with hematologic malignancies and systemic
opportunistic infections treated with donor granulocyte transfusions: Cancer
(106):2664-71.

Santolaya, M.E., Alvarez, A.M., Becker, A., Cofre, J., Enriquez, N., O'Ryan, M.et
al. 2001. Prospective, multicenter evaluation of risk factors associated with
invasive bacterial infection in children with cancer, neutropenia, and fever:
J.Clin.Oncol. (19):3415-21.

Sastroasmoro, Aminullah A., Rukman Y., Munasir Z., 2006, Variabel dan
hubungan antar variabel, dalam Sastroasmoro S dan Ismael S (Editor),
Dasar-dasar Metodologi Penelitian Klinis: Jakarta, Sagung Seto, hal. 220-
38.

Schwartzberg, L.S., 2006. Neutropenia: etiology and pathogenesis:

Clin.Cornerstone. (8 Suppl 5):S5-11.

Scott, S., 2002. Identification of cancer patients at high risk of febrile neutropenia:
Am.J Health Syst.Pharm. (59):S16-S19.
 51

Siena, S., Secondino, S., Giannetta, L., Carminati, O., Pedrazzoli, P., 2003.
Optimising management of neutropenia and anaemia in cancer
chemotherapy-advances in cytokine therapy: Crit Rev.Oncol.Hematol.
(48):S39-S47.

Soemantri, 2004, Epidemiology of iron deficiency anemia, Medika, hal. 2-8.

Sundberg, Estrada, Abramo, 2009. Pediatric fever and neutropenia: an evidence-

based approach: EB Medicine.net (11):1-15.

Suradi, Siahaan CM., Boedjang RF., 2006, Penelitian kasus kontrol, dalam
Sastroasmoro S. dan Ismael S. (Editor), Dasar-dasar Metodologi Penelitian
Klinis: Jakarta, Sagung Seto, hal. 110-26.

Teuffel, O., Kuster, S.P., Hunger, S.P., Conter, V., Hitzler, J., Ethier, M.C.et al.
2011. Dexamethasone versus prednisone for induction therapy in childhood
acute lymphoblastic leukemia: a systematic review and meta-analysis:
Leukemia (25):1232-8.

van Tilburg, C.M., Sanders, E.A., Nibbelke, E.E., Pieters, R., Revesz, T., Westers,
P.et al. 2011. Impact of reduced chemotherapy treatment for good risk
childhood acute lymphoblastic leukaemia on infectious morbidity*: Br.J
Haematol. (152):433-40.

Viscoli, C., Bruzzi, P., Castagnola, E., Boni, L., Calandra, T., Gaya, H.et al.
1994. Factors associated with bacteraemia in febrile, granulocytopenic
cancer patients. The International Antimicrobial Therapy Cooperative
Group (IATCG) of the European Organization for Research and Treatment
of Cancer (EORTC): Eur.J Cancer (30A):430-7.

Widjajanto, Supriyadi, Purwanto, Cloos, vd Ven, Sutaryoet al. 2012a.

Dexamethasone versus prednisone in childhood acute lymphoblastic
leukemia treatment:results of the Indonesian randomized trial:
unpublished92-108.

Widjajanto, P.H., Sutaryo, S., Purwanto, I., Ven, P.M., Veerman, A.J., 2012b.
Early Response to Dexamethasone as Prognostic Factor: Result from
Indonesian Childhood WK-ALL Protocol in Yogyakarta: J Oncol.
(2012):417941.

Yetgin, S., Cetin, M., 2003. The dose related effect of steroids on blast reduction
rate and event free survival in children with acute lymphoblastic leukemia:
Leuk.Lymphoma (44):489-95.